Immuno-Oncology | Specialty

Dr. Nambiar on Next Steps with Galectin-1 for Head and Neck Cancer

April 21st 2017

Dhanya K. Nambiar, PhD, Stanford University, discusses the next steps with targeting galectin-1 with radiation therapy and immune checkpoint inhibitors in patients with head and neck cancer.

Dr. Abi-Jaoudeh Discusses Potential of Immunotherapy in Advanced HCC

April 20th 2017

Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the potential for immunotherapy in advanced hepatocellular carcinoma.

Future Directions for Metastatic Breast Cancer

April 19th 2017

Unmet Needs for Metastatic Breast Cancer

April 19th 2017

Patient Selection for Eribulin in Breast Cancer

April 19th 2017

Preclinical Observations on Eribulin for Breast Cancer

April 19th 2017

Dual MOA for Eribulin in Breast Cancer

April 19th 2017

Role of MOA When Choosing Breast Cancer Chemotherapy

April 19th 2017

Evolution of Chemotherapy for Metastatic Breast Cancer

April 19th 2017

Optimizing Chemotherapy for Metastatic Breast Cancer

April 19th 2017

Chemotherapy Use for Breast Cancer Subtypes

April 19th 2017

Chemotherapy for Metastatic Breast Cancer in 2017

April 19th 2017

Dr. Costa on Biomarkers Beyond PD-L1 for Immunotherapy in NSCLC

April 19th 2017

Daniel B. Costa, MD, PhD, MMSc, associate professor of medicine at Harvard Medical School, medical staff, Hematology/Oncology, medical director of the Cancer Clinical Trials Office, and Medical Center Thoracic Oncology Group Leader, of Beth Israel Deaconess Medical Center, discusses biomarkers beyond PD-L1 in development for immunotherapy in patients with non–small cell lung cancer (NSCLC).

Tripathy Offers Insights on Future of Breast Cancer From SABCS, ASCO

April 19th 2017

The 34th Annual Miami Breast Cancer Conference® featured a recap of significant research from the 2016 ASCO Annual Meeting and the 2016 San Antonio Breast Cancer Symposium.

Dr. Monk on Immunotherapy for Gynecologic Cancer

April 19th 2017

Bradley J. Monk, MD, FACOG, FACS, professor, director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses immunotherapy for patients with gynecologic cancer.

Brahmer Highlights 5-Year Nivolumab Findings in NSCLC

April 18th 2017

Julie R. Brahmer, MD, discusses the 5-year findings of nivolumab in non-small cell lung cancer, their significance, and expected next steps for this research.

FDA Approves Frontline Atezolizumab for Some Bladder Cancer Patients

April 18th 2017

The FDA has granted an accelerated approval to atezolizumab as a frontline treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Dr. Siefker-Radtke on FDA Approval of Frontline Atezolizumab in Bladder Cancer

April 18th 2017

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses the FDA approval of the PD-L1 inhibitor atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma as a frontline therapy or following progression occurring ≥12 months after neoadjuvant or adjuvant chemotherapy.

BCL-2 Inhibitors May Provide Avenue of Attack Against High-Risk Neuroblastoma

April 17th 2017

Investigators at Virginia Commonwealth University Massey Cancer Center discuss the current treatment for children with high-risk neuroblastoma including high-dose chemotherapy, surgery, stem cell transplantation, radiation therapy, isotretinoin, and immunotherapy.

Immunotherapy Agents, Combinations to Compete for Frontline NSCLC

April 17th 2017

Sukhmani Padda, MD discusses the status of ongoing clinical trials participating in this race to the frontline setting in lung cancer.